Abstract:It has been known for more than a decade that AAV genomes in ssAAV particles are heterogeneous, and can contain smaller than unit-length molecules to varying degrees. However, the cause underlying this phenomenon remained unknown. Our earlier work demonstrated that short DNA hairpin (shDNA) sequences designed into rAAV vectors, resulted in truncated genomes through a template-switching mechanism during AAV genome replication. Importantly, the knowledge we have gained about shDNA-mediated genomic truncation has helped to improve shRNA-cassette design. Specifically, we have found a correlation between the thermal stability of shDNA structures with the prevalence of truncation events. By introducing point mutations into the passenger strand of shRNA sequences to create DNA bulges within shDNAs in scAAV vectors, we found that lowering the thermal stability of DNA hairpins lowered the proportion of truncated to complete genomes. In addition, we found that scAAV vectors incorporated with pri-miRNA transgenes, which contain natural bulges in their stem-loop structures, also produced fewer truncated genomes, relative to shDNA-rAAV constructs. By embedding the guide strand of small RNAs into pri-miRNA scaffolds, we have defined critical improvements to the genomic integrity of rAAV vectors expressing small RNAs. Furthermore, we developed a method, named AAV-GPSeq (AAV genome populations sequencing), to directly sequence whole vector genome populations from purified rAAVs using the PacBio platform for high-throughput sequencing. We discovered through this methodology that truncation events can originate from palindromic sequences and inverted repeats that reside in the expression cassette elements of widely used ssAAV and scAAV vector designs (i.e. transcriptional regulatory elements, transgene sequences, and post-transcriptional regulatory regions). The resulting diversity of genomic truncations produces populations of packaged virions with variable transgene efficacies, and gives us the first insights into the phenomenon of rAAV heterogeneity. By examining the genomes from rAAV vectors harboring shDNAs, pri-miRNA fragments, and palindromic/inverted repeat sequences, we now highlight the importance of DNA secondary structure on vector design and genomic heterogeneity in packaged viral vectors. Improvements upon quality control standards are thus necessary and critical to efficacious and safe clinical uses for rAAV as a biomedicine. Further implications for our novel findings towards understanding AAV replication, and new considerations for future therapeutic rAAV vector designs will be discussed. To improve the homogeneity of clinical rAAV vectors, we are optimizing the vector production procedure, testing non-palindrome promoters, changing the codon usage in transgenes to lower the thermostability of rAAV genomes, and modifying rAAV packaging cell lines to minimize template-switching events to produce more intact rAAV genomes.

Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver.

Inhibition of Hepatitis C Virus Replication Using Adeno-Associated Virus Vector Delivery of an Exogenous Anti-Hepatitis C Virus Microrna Cluster

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

A self-complementary AAV proviral plasmid that reduces cross-packaging and ITR promoter activity in AAV vector preparations

Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells

677. Stabilizing the Raav Vector Genome Increases AAV Vector Transduction Efficiency

Adeno-Associated Virus Vector-Mediated Sirna Inhibition Of Hepatitis B Virus Gene Expression In Vitro

Preparation of Raav/hflx by HSV/AAV Hybrid Helper Virus and Evaluation of Its Safety

B cell focused transient immune suppression protocol for efficient AAV readministration to the liver

Optimization of the Capsid of Recombinant Adeno-Associated Virus 2 (AAV2) Vectors: the Final Threshold?

rAAV capsid mutants eliminate leaky expression from DNA donor template for homologous recombination

9. rAAV Designs Harboring DNA Secondary Structures with High Thermal Stabilities Produce Heterogenic Viral Genome Populations

Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins

Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity

Inhibition of HBV Replication and Gene Expression in Vitro and in Vivo with a Single AAV Vector Delivering Two Shrna Molecules.

A Lac Repressor-Inducible Baculovirus Expression Vector for Controlling Adeno-Associated Virus Capsid Ratios

Enhanced Transgene Expression from Recombinant Single-Stranded D-sequence-substituted Adeno-Associated Virus Vectors in Human Cell Lines in Vitro and in Murine Hepatocytes in Vivo.

Tuning capsid formation dynamics in recombinant adeno‐associated virus producing synthetic cell lines to enhance full particle productivity

Development of an adipose-tropic AAV capsid ablating liver tropism